uniQure NV (FRA:UQ1)
€ 14.66 0 (0%) Market Cap: 814.57 Mil Enterprise Value: 462.08 Mil PE Ratio: 0 PB Ratio: 15.15 GF Score: 65/100

Q2 2022 Uniqure NV Earnings Call Transcript

Aug 08, 2022 / 12:30PM GMT
Release Date Price: €19.5 (-19.09%)
Operator

Good day, and thank you for standing by. Welcome to the AMT-130 Huntington's Disease Program Update.

(Operator Instructions)

Please be advised that today's conference is being recorded. And I would now like to hand the conference over to Ms. Maria Cantor, Chief Corporate Affairs Officer. Ms. Cantor, please go ahead.

Maria E. Cantor
uniQure N.V. - Chief Corporate Affairs Officer

Good morning, and thank you for joining us. This morning, uniQure announced that it has postponed patient enrollment in the higher-dose cohort of the Phase I/II clinical trial of AMT-130 in Huntington's disease based on reported SUSAR events at this dose. We will discuss these events and provide an update on the program during this call. Joining me for the investor event and webcast are Matt Kapusta, our Chief Executive Officer; and Dr. Ricardo Dolmetsch, our President of Research and Development.

We'll be making forward-looking statements during this investor call. All statements, other than those of historical fact are forward-looking statements. They are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot